KCNIP3 and Huntington disease: This decreased expression level of DREAM might be interpreted as a defense mechanism since the genetic knockdown or pharmacological inhibition of DREAM with repaglinide or with the most potent DREAM inhibitor, IQM-PC330, delays the onset of motor dysfunction and reduces striatal neuronal death in a mouse model of HD [65,66].